Guangzhou Baiyunshan Pharmaceutical Holdings Co 600332.SS · CNY
Health Care · Shanghai · 🇨🇳 China
19.91
-0.90%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Guangzhou Baiyunshan Pharmaceutical Holdings Co
Its shares trade on Shanghai under the ticker 600332.SS. It has been listed since 6 February 2001. In the fiscal year to 31 December 2025, it reported revenue of CN¥77.45bn and net income of CN¥2.98bn. At that date it held total assets of CN¥84.51bn and shareholders' equity of CN¥37.79bn.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2001-02-06. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is engaged in the pharmaceutical and healthcare industry. The firm's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The firm's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The firm's Great Health segment includes research, development, manufacturing and sales for the products of Great Health. The firm's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The firm has an antibiotic production chain ranging from raw material medicine to preparation, with products covering commonly used antibiotics. The company is engaged in the research and development (R&D), and manufacturing of beverage and food, among others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 Feb 2001
- Employees
- 25,853
- Website
- gybys.com.cn ↗
Leadership
Pay as last reported
- Mr. Xiaojun LiExecutive Chairman of the Board, since 2025
- Ms. Ning ChengExecutive Vice Chairman of the Board, since 2012CN¥1.5m
- Mr. Jun YangExecutive Vice Chairman of the Board, since 2020CN¥1.6m
- Ms. Fei LiuChief Financial OfficerCN¥845,270
- Mr. Hong LiGeneral Manager, Executive Director, since 2017CN¥1.3m
- Ms. Haoshan ZhengDeputy General ManagerCN¥1.2m
- Mr. Jianxiong ZhengDeputy General ManagerCN¥1.5m
- Ms. Xuezhen HuangSecretary of the BoardCN¥1.0m
- Mr. Yajin ChenIndependent Non-Executive DirectorCN¥120,000
- Mr. Min HuangIndependent Non-Executive DirectorCN¥120,000
- Ms. Baoqing SunIndependent Non-Executive DirectorCN¥120,000
- Mr. Lung Tak WongIndependent Non-Executive DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 74
- Environment
- 99
- Social
- 66
- Governance
- 55
- Direct emissions (scope 1)
- 171,468.81 t
- Energy emissions (scope 2)
- 123,327.38 t
- Value chain emissions (scope 3)
- 17,042.21 t
- Women in the workforce
- 42.68%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (Baiyunshan) holds several key strengths that contribute to its success in the pharmaceutical industry.
- Established Brand: Baiyunshan has built a strong brand image and is recognized as one of the leading pharmaceutical companies in China. Its brand reputation and trust among consumers give it a competitive edge in the market.
- Diverse Product Portfolio: The company offers a wide range of pharmaceutical products, including medicines, health supplements, and traditional Chinese medicines. This diversification provides a stable revenue stream and reduces dependence on any single product category.
- Research and Development (R&D) Capabilities: Baiyunshan invests significantly in R&D, enabling it to develop innovative products and stay ahead of competitors. Its strong R&D capabilities enhance product quality and allow for the introduction of new drugs.
- Established Distribution Network: Baiyunshan has an extensive distribution network across China, including partnerships with hospitals, pharmacies, and online platforms. This wide reach ensures efficient product distribution and market penetration.
Weaknesses
- Despite its strengths, Baiyunshan also faces several weaknesses that may pose challenges to its growth and competitiveness.
- Heavy Reliance on Domestic Market: The company primarily operates within China, making it vulnerable to fluctuations in the domestic market. Expanding into international markets could help mitigate this risk.
- Limited Global Presence: Baiyunshan has limited brand recognition and market presence outside of China. This limits its potential for international expansion and partnerships with global pharmaceutical companies.
- Regulatory Challenges: The pharmaceutical industry is subject to stringent regulations and quality control measures. Compliance with these regulations can be time-consuming and costly, impacting the company's profitability.
Opportunities
- Baiyunshan can leverage several opportunities to further strengthen its position in the market.
- Growing Chinese Pharmaceutical Market: The Chinese pharmaceutical market continues to expand rapidly with increasing healthcare expenditure and a larger aging population. Baiyunshan can tap into this market growth by introducing new products and targeting specific healthcare needs.
- International Expansion: Exploring opportunities for expansion into international markets can diversify the company's revenue streams and reduce dependence on the domestic market. This may involve collaborations, partnerships, or acquisitions with global pharmaceutical players.
- Embracing Digital Transformation: The rise of digital technologies presents opportunities to streamline operations, improve supply chain efficiency, and enhance customer experience. Baiyunshan should invest in digital solutions to stay competitive and cater to evolving consumer demands.
Threats
- Baiyunshan faces certain threats that could impact its growth and profitability.
- Intense Competition: The pharmaceutical industry is highly competitive, with numerous local and international players vying for market share. Baiyunshan must continuously innovate and develop differentiated products to stay ahead of the competition.
- Patent Expirations: The expiration of patents on key products can lead to increased competition from generic drug manufacturers. Baiyunshan needs to invest in R&D to create new products and maintain a competitive edge.
- Pricing Pressure: Pricing pressures and government regulations can impact the profitability of pharmaceutical companies. Baiyunshan should monitor pricing trends and optimize its cost structures to remain profitable.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.